| Identification | Back Directory | [Name]
ZOTEPINE | [CAS]
26615-21-4 | [Synonyms]
Setous
lodopin
zotepina
ZOTEPINE
Majorpin
f)thiepin,2-chloro-11-(2-(dimethylamino)ethoxy)-dibenzo(
8-Chloro-10-[2-(dimethylamino)ethoxy]dibenzo[b,f]thiepin
2-chlor-11-(2-dimethylaminoaethoxy)-dibenzo(b,f)-thiepin
2-chloro-11-(2-(dimethylamino)ethoxy)dibenzo(b,f)thiepin
2-chloro-11-(2-dimethylaminoethoxy)-dibenzo(b,f)thiepine
N,N-Dimethyl-2-(2-chlorodibenzo[b,f]thiepin-11-yloxy)ethylamine
2-(8-chlorobenzo[b][1]benzothiepin-6-yl)oxyethyl-dimethyl-amine
2-((8-chlorodibenzo(b,f)thiepin-10-yl)oxy)-n,n-dimethylethanamine
2-(8-chlorobenzo[b][1]benzothiepin-6-yl)oxy-N,N-dimethylethanamine
2-(8-chlorobenzo[b][1]benzothiepin-6-yl)oxy-N,N-dimethyl-ethanamine
2-[(8-Chlorodibenzo(Z)[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine
Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl-
2-[(3-chloro-5-benzo[b][1]benzothiepinyl)oxy]-N,N-dimethylethanamine | [Molecular Formula]
C18H18ClNOS | [MDL Number]
MFCD00868143 | [MOL File]
26615-21-4.mol | [Molecular Weight]
331.86 |
| Chemical Properties | Back Directory | [Melting point ]
90-91° | [Boiling point ]
478.4±45.0 °C(Predicted) | [density ]
1.0675 (rough estimate) | [refractive index ]
1.6100 (estimate) | [storage temp. ]
Store at RT | [solubility ]
DMSO: ≥20mg/mL | [form ]
powder | [pka]
8.72±0.28(Predicted) | [color ]
white to off-white |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
25-50/53 | [Safety Statements ]
45-60-61 | [RIDADR ]
UN 2811 6.1 / PGIII | [WGK Germany ]
3 | [Toxicity]
LD50 in male mice, rats (mg/kg): 108, 458 orally; 43.3, 39.7 i.v.; 40.0, 97.0 i.p.; 84.9, 2080 s.c. (Fukuhara) |
| Hazard Information | Back Directory | [Chemical Properties]
White to off white crystalline powder | [Originator]
Lodopin,Fujisawa Pharmaceutical,Japan,1982 | [Uses]
antipsychotic;Dopamine D2/serotonin 5-HT2 antagonist | [Definition]
ChEBI: Zotepine is a dibenzothiepine and a tertiary amino compound. It has a role as an alpha-adrenergic drug, a serotonergic drug and a second generation antipsychotic. | [Manufacturing Process]
A suspension of 30 g of sodium hydride in benzene (30 ml) was added
dropwise to 52 g of 8-chlorodibenzo[b,f]thiepin-10(11H)-one dissolved in
dimethylformamide (800 ml), and the mixture was heated at 100°C for 2
hours. To this, there were added 68 g of 2-dimethylaminoethyl chloride, and
the mixture was heated at 60°C for 39 hours. The reaction mixture, after
cooled, was poured into ice-water, and the solution was extracted with ethyl
acetate. The ethyl acetate layer, after washed with water, was extracted with
10% hydrochloric acid, when oil was precipitated. The aqueous layer, in which
oil was precipitated, was washed with ether, made neutral with concentrated
sodium hydroxide solution and then extracted with ethyl acetate. The ethyl
acetate layer was washed with water, dried over magnesium sulfate, and
concentrated to give oil, which was allowed to stand to provide solid. The solid
was washed with petroleum ether and recrystallized from cyclohexane to yield
42.5 g of 8-chloro-10-(2-dimethylaminoethyl)-oxydibenzo[b,f]thiepin as
crystals, melting point 90°C to 91°C. Maleate as colorless needle, melting
point 204°C to 204.5°C. | [Therapeutic Function]
Tranquilizer |
|
|